

## Items supported by the Samaritan Fund

- (a) Non-drug Items supported by the Fund
  - (i) One-off Non-drug Items
  - (ii) Non-one-off Non-drug Items
- (b) Self-financed Drugs supported by the Samaritan Fund (SF) and Community Care Fund (CCF) Medical Assistance Programme (First Phase Programme) (for specified self-financed cancer drugs)

### (a) Non-drug Items supported by the Fund

#### (i) One-off Non-drug Items

*[Financial assessment of the Fund will be based on **patient's household income and asset, with reference to the Median Monthly Domestic Household Income (MMDHI) and the estimated cost / deposit (if applicable) of the item concerned respectively.]***

1. Percutaneous Transluminal Coronary Angioplasty (PTCA) and other consumables for interventional cardiology
2. Cardiac Pacemakers
3. Myoelectric Prosthesis
4. Custom-made Prosthesis
5. Appliances for prosthetic and orthotic services, physiotherapy and occupational therapy services (including prosthesis, wheelchair, mobility & transfer aids, self care aids, therapeutic furniture, and training & treatment device & equipment)
6. Home use equipment and appliances (including hearing devices & accessories, respiratory equipment, communication aids, and infusion pump for enteral/parenteral nutrition)
7. Gamma knife surgery
8. Harvesting of marrow in a foreign country for marrow transplant

#### (ii) Non-one-off Non-drug Items

*[Financial assessment of the Fund will be based on **patient's household annual disposable financial resources (ADFR).**]*

1. Proton Beam Therapy
2. Tumor Treating Fields

The Fund will only support the model which can meet the basic medical needs of the patients.

**(b) Drugs supported by the Samaritan Fund (As at 26 April 2025)**

The following specific self-financed drugs are supported by the Samaritan Fund:

Item	Drug	Specialties	Clinical indications
1a	Abatacept	Rheumatology	Rheumatoid arthritis
1b		Paediatrics	Juvenile idiopathic arthritis
2a	Abemaciclib <sup>#</sup>	Oncology	HR positive HER2 negative locally advanced or metastatic breast cancer (MBC)
2b	Abemaciclib <sup>#</sup>		
3	Fulvestrant		
4	Abiraterone <sup>#</sup>	Oncology	Prostate cancer
5	Abrocitinib	Dermatology	Atopic dermatitis
6a	Acalabrutinib <sup>#</sup>	Haematology	Relapsed / refractory chronic lymphocytic leukaemia (CLL)
6b			Previously untreated chronic lymphocytic leukaemia (CLL) with unmutated IGHV
7a	Adalimumab	Dermatology / Paediatrics	Severe psoriasis
			Hidradenitis suppurativa (acne inversa)
7b		Ophthalmology	Non-infectious intermediate, posterior and panuveitis
7c			Paediatric chronic non-infectious anterior uveitis
7d		Paediatrics	Juvenile idiopathic arthritis
7e		Rheumatology	Ankylosing spondylitis
7f			Psoriatic arthritis
7g			Rheumatoid arthritis
8	Afatinib	Oncology	Non-small cell lung cancer with activating EGFR mutation (first-line treatment)
9a	Aflibercept	Ophthalmology	Neovascular (wet) age-related macular degeneration
9b			Macular oedema secondary to Central Retinal Vein Occlusion

Item	Drug	Specialties	Clinical indications
9c			Visual impairment caused by diabetic macular oedema
10a	Alectinib <sup>#</sup>	Oncology	ALK+ve non-small cell lung cancer (NSCLC) (first-line treatment)
10b			ALK+ve metastatic non-small cell lung cancer (NSCLC), progressed on Crizotinib and intolerant to Ceritinib, or have CNS-progression after Crizotinib
11	Anifrolumab	Rheumatology	Systemic lupus erythematosus (SLE)
12	Apalutamide <sup>#</sup>	Oncology	Prostate cancer
13	Atezolizumab	Oncology	EGFR-ve and ALK-ve metastatic non-small cell lung cancer (NSCLC) progressed on or following platinum-based chemotherapy
14	Axitinib <sup>#</sup>	Oncology	Advanced renal cell carcinoma
15 & 16	Azacitidine and Venetoclax	Haematology	Newly diagnosed acute myeloid leukaemia (AML)
17	Baricitinib	Rheumatology	Rheumatoid arthritis
18	Belimumab	Paediatrics / Rheumatology	Systemic lupus erythematosus (SLE)
19	Bendamustine and Obinutuzumab	Haematology	Follicular lymphoma
20a			
20b	Obinutuzumab		
20c	Obinutuzumab	Haematology	Chronic lymphocytic leukaemia (CLL)
21	Benralizumab	Respiratory Medicine	Severe refractory eosinophilic asthma (add-on treatment)
22	Bevacizumab <sup>~</sup>	Oncology <sup>~</sup>	Advanced epithelial ovarian / fallopian tube / primary peritoneal cancer (front-line treatment in combination with chemotherapy) <sup>~</sup>
23a	Bortezomib	Haematology	Multiple myeloma (MM)
24a	Brentuximab Vedotin	Haematology	Systemic anaplastic large cell lymphoma (sALCL)

Item	Drug	Specialties	Clinical indications
24b			CD30+ cutaneous T-cell lymphoma (CTCL)
24c			CD30+ Hodgkin lymphoma
25a	Brigatinib <sup>#</sup>	Oncology	ALK+ve non-small cell lung cancer (NSCLC) (first-line treatment)
25b			ALK+ve metastatic non-small cell lung cancer (NSCLC), progressed on Crizotinib and intolerant to Ceritinib, or have CNS-progression after Crizotinib
26a	Canakinumab	Paediatrics	Cryopyrin-associated periodic syndromes
26b			Familial Mediterranean fever
26c			Hyperimmunoglobulin D syndrome / mevalonate kinase deficiency
26d			Systemic juvenile idiopathic arthritis
26e			Tumour necrosis factor receptor associated periodic syndrome
27	Carfilzomib	Haematology	Multiple myeloma (MM)
28a	Ceritinib <sup>#</sup>	Oncology	ALK+ve non-small cell lung cancer (NSCLC) (first line treatment)
28b			ALK+ve advanced non-small cell lung cancer (NSCLC) previously treated with Crizotinib
29a	Certolizumab Pegol	Rheumatology	Ankylosing spondylitis
29b			Psoriatic arthritis
29c			Rheumatoid arthritis
30	Cetuximab	Oncology	RAS wild-type colorectal cancer
31	Cladribine	Neurology	Relapsing-remitting multiple sclerosis (RRMS)
32a	Crizotinib <sup>#</sup>	Oncology	ALK+ve non-small cell lung cancer (NSCLC)
32b			ROS1-positive non-small cell lung cancer (NSCLC)

Item	Drug	Specialties	Clinical indications
33a	Dabrafenib <sup>#</sup> and Trametinib <sup>#</sup>	Oncology	BRAF V600 mutation-positive unresectable or metastatic melanoma
34a			
33b			Stage III melanoma with a BRAF V600 mutation, following complete resection (adjuvant treatment)~
34b			
35	Daratumumab and Bortezomib	Haematology	Systemic AL amyloidosis
23b			
36a	Dasatinib	Haematology	Imatinib-resistant chronic myeloid leukaemia (CML)
36b			Imatinib-resistant philadelphia or BCR/ABL positive acute lymphoblastic leukaemia (ALL)
36c			Newly diagnosed chronic myeloid leukaemia (CML) in chronic phase
36d			Nilotinib-resistant chronic myeloid leukaemia (CML)
37a	Dexamethasone <sup>^</sup>	Ophthalmology <sup>^</sup>	Macular oedema following Central Retinal Vein Occlusion <sup>^</sup>
37b			Diabetic macular oedema (second-line treatment)
38a	Dupilumab	Dermatology / Paediatrics	Atopic dermatitis
38b		Respiratory Medicine	Severe asthma with type 2 inflammation (add-on treatment)
39	Durvalumab	Oncology	Unresectable and stage III non-small cell lung cancer (NSCLC) not progressed following concurrent platinum-based chemotherapy and radiation therapy
40	<b>Specific ultra-expensive drug</b> <i>(The patient must be a permanent resident of the Hong Kong Special Administrative Region according to the Immigration Ordinance)</i>		
	Eculizumab	Haematology	Paroxysmal nocturnal haemoglobinuria (PNH)

Item	Drug	Specialties	Clinical indications
41a	Eltrombopag	Haematology	Chronic immune thrombocytopenia (for post-splenectomised patients; or non-splenectomised patients in whom splenectomy is contraindicated)
41b			Severe aplastic anaemia (SAA) <sup>#</sup>
42	Enzalutamide <sup>#</sup>	Oncology	Prostate cancer
43a	Etanercept	Dermatology	Severe psoriasis
43b		Paediatrics	Juvenile idiopathic arthritis
43c		Rheumatology	Ankylosing spondylitis
43d			Psoriatic arthritis
43e			Rheumatoid arthritis
44	Everolimus <sup>#</sup>	Oncology	HR positive HER2 negative advanced breast cancer
45a	Faricimab	Ophthalmology	Neovascular (wet) age-related macular degeneration
45b			Visual impairment caused by diabetic macular oedema
46	Gemtuzumab Ozogamicin <sup>~</sup>	Haematology <sup>~</sup>	Acute myeloid leukaemia (AML) <sup>~</sup>
47	Gilteritinib <sup>#</sup>	Haematology	Relapsed or refractory acute myeloid leukaemia (AML)
48a	Golimumab	Rheumatology	Ankylosing spondylitis
48b			Psoriatic arthritis
48c			Rheumatoid arthritis
49	Growth Hormone	Endocrinology	Dwarfism
50a	Guselkumab	Dermatology	Severe psoriasis
50b		Rheumatology	Psoriatic arthritis
51a	Ibrutinib <sup>#</sup>	Haematology	Relapsed or refractory mantle cell lymphoma (MCL)
51b			Chronic lymphocytic leukaemia (CLL)
52a	Infliximab	Dermatology	Severe psoriasis
52b		Rheumatology	Ankylosing spondylitis
52c			Psoriatic arthritis

Item	Drug	Specialties	Clinical indications
52d			Rheumatoid arthritis
53	Inotuzumab Ozogamicin	Haematology	Relapsed or refractory CD22-positive B cell Acute lymphoblastic leukaemia (ALL)
54	Interferon	Paediatrics	Chronic granulomatous disease
55	Ixekizumab	Dermatology	Severe psoriasis
56a	Lenalidomide <sup>#</sup>	Haematology	Multiple myeloma (MM)
56b 23c	Lenalidomide <sup>#</sup> and Bortezomib		
57	Lenvatinib <sup>#</sup>	Oncology	Unresectable hepatocellular carcinoma (HCC)
58	Letermovir	Haematology	Prophylaxis of cytomegalovirus reactivation and disease in recipients of an allogeneic haematopoietic stem cell transplant
59	Lorlatinib <sup>#^</sup>	Oncology <sup>^</sup>	Metastatic non-small cell lung cancer (NSCLC) whose tumors are ALK-positive and with baseline brain metastasis <sup>^</sup>
60a	Luspatercept <sup>^</sup>	Haematology <sup>^</sup>	Transfusion-dependent anaemia associated with beta-thalassaemia <sup>^</sup>
60b			Transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndrome (MDS) with ring sideroblasts <sup>^</sup>
61a	Mepolizumab	Respiratory Medicine	Severe refractory eosinophilic asthma (add-on treatment)
61b		Rheumatology <sup>^</sup>	Relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (EGPA) (add-on treatment) <sup>^</sup>
62a	Midostaurin <sup>#</sup>	Haematology	Acute myeloid leukaemia (AML)

Item	Drug	Specialties	Clinical indications
62b			Aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM-AHN), or mast cell leukaemia (MCL)^
63a	Nilotinib	Haematology	Dasatinib-resistant chronic myeloid leukaemia (CML)
63b			Imatinib-resistant chronic myeloid leukaemia (CML)
63c			Newly diagnosed chronic myeloid leukaemia (CML) in chronic phase
64a	Nintedanib (Ofev)	Respiratory Medicine	Idiopathic pulmonary fibrosis (IPF)
64b		Rheumatology	Rheumatic disease associated progressive fibrosing interstitial lung disease (PF-ILD)
65a	Nivolumab	Oncology	Unresectable or metastatic melanoma
65b			Adjuvant treatment of melanoma with involvement of lymph nodes or metastatic disease, have undergone complete resection
65c			EGFR-ve and ALK-ve metastatic non-small cell lung cancer (NSCLC) progressed on or following platinum-based chemotherapy
65d			Recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after platinum based therapy~
65e			In combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma whose tumors express CPS $\geq$ 10^
65f 66a	Nivolumab and Ipilimumab^	Oncology^	Unresectable malignant pleural mesothelioma (first-line treatment)^



Item	Drug	Specialties	Clinical indications
65g 66b			Intermediate or poor risk advanced renal cell carcinoma (first-line treatment)~
67	Olaparib <sup>#</sup>	Oncology	Epithelial ovarian, fallopian tube or primary peritoneal cancer
68a	Omalizumab	Respiratory Medicine	Severe persistent confirmed allergic IgE mediated asthma
68b		Clinical Immunology	Chronic spontaneous urticaria
69a	Osimertinib <sup>#</sup>	Oncology	Locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC) (Progressed after previous treatment with an EGFR tyrosine kinase inhibitor (TKI) )
69b			EGFR mutation positive non-small cell lung cancer (NSCLC) with CNS metastases (First-line treatment)
70	Paclitaxel (Albumin)	Oncology	Pancreatic cancer
71	Palbociclib <sup>#</sup>	Oncology	HR positive HER2 negative locally advanced or metastatic breast cancer (MBC)
72	Panitumumab	Oncology	RAS wild-type colorectal cancer
73	Pazopanib	Oncology	Advanced renal cell carcinoma
74a	Pembrolizumab	Oncology	First-line treatment for metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression with no EGFR or ALK genomic tumor aberrations
74b			Bladder cancer
75a 76a	Pertuzumab and Trastuzumab	Oncology	HER2 over-expressed metastatic breast cancer (MBC)
75b 76b			HER2 positive, locally advanced, inflammatory, or early stage breast cancer

Item	Drug	Specialties	Clinical indications
77a	Plerixafor	Haematology	Multiple myeloma (MM)
77b			Non-Hodgkin's lymphoma (NHL)
78	Pomalidomide <sup>#</sup>	Haematology	Multiple myeloma (MM)
79a	Ponatinib	Haematology	Acute lymphoblastic leukaemia (ALL)
79b			Chronic myeloid leukaemia (CML)
80a	Ranibizumab	Ophthalmology	Neovascular (wet) age-related macular degeneration
80b			Macular oedema secondary to Central Retinal Vein Occlusion
80c			Visual impairment caused by diabetic macular oedema
81a	Ribociclib <sup>#</sup>	Oncology	HR positive HER2 negative locally advanced or metastatic breast cancer (MBC)
81b 3	Ribociclib <sup>#</sup> and Fulvestrant		
82a	Risankizumab	Dermatology	Severe psoriasis
82b		Rheumatology	Psoriatic arthritis
83a	Rituximab	Dermatology	Pemphigus vulgaris
83b		Haematology	Maintenance therapy for relapsed follicular lymphoma (RFL)
83c			Previously-untreated and relapsed / refractory chronic lymphocytic leukaemia (CLL)
83d		Oncology	Malignant lymphoma (ML)
83e		Paediatrics	Severe, active granulomatosis with polyangiitis (GPA)/microscopic polyangiitis (MPA)
83f			CD20 positive diffuse large B-cell lymphoma, Burkitt lymphoma / Burkitt leukaemia or Burkitt-like lymphoma
83g		Rheumatology	Refractory rheumatoid arthritis (RRA)
83h			Severe, active non-life-threatening granulomatosis with polyangiitis/microscopic polyangiitis

Item	Drug	Specialties	Clinical indications
84a	Ruxolitinib <sup>#</sup>	Haematology	Myelofibrosis-related splenomegaly or symptoms
84b			Graft versus host disease
85	Sarilumab	Rheumatology	Rheumatoid arthritis
86a	Secukinumab	Dermatology / Paediatrics	Severe psoriasis
86b		Rheumatology	Ankylosing spondylitis
86c			Psoriatic arthritis
87	Siltuximab	Haematology	Multicentric Castleman's disease (MCD)
88	Siponimod	Neurology	Secondary progressive multiple sclerosis (SPMS)
89	Sunitinib	Oncology	Gastrointestinal tumour
90	Temozolomide	Oncology	Recurrent high grade glioma
91a	Tocilizumab	Paediatrics	Juvenile idiopathic arthritis(JIA)
91b			Systemic juvenile idiopathic arthritis (JIA)
91c		Rheumatology	Refractory giant cell arteritis
91d			Rheumatoid arthritis
92a	Tofacitinib	Rheumatology	Rheumatoid arthritis
92b			Psoriatic arthritis
93	Tolvaptan (Jinarc)	Nephrology	Autosomal dominant polycystic kidney disease (ADPKD)
76c	Trastuzumab	Oncology	HER2 over-expressed metastatic breast cancer (MBC)
76d			HER2 positive early breast cancer (EBC)
94	Trastuzumab Deruxtecan <sup>^</sup>	Oncology <sup>^</sup>	As monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one prior anti-HER2-based regimen <sup>^</sup>
95a	Trastuzumab emtansine	Oncology	HER2 positive early breast cancer (EBC)

Item	Drug	Specialties	Clinical indications
95b	(T-DM1)		HER2 positive metastatic breast cancer (MBC)
96a	Upadacitinib	Rheumatology	Ankylosing spondylitis
96b			Psoriatic arthritis
96c			Rheumatoid arthritis
96d		Dermatology/ Paediatrics	Atopic dermatitis
97a	Ustekinumab	Dermatology	Severe psoriasis
97b		Rheumatology	Psoriatic arthritis
98	Zanubrutinib <sup>#</sup>	Haematology	Waldenstrom's macroglobulinaemia (WM)

Remarks:

^ With effect from 14 December 2024.

~ **Bevacizumab** for treating epithelial ovarian/ fallopian tube/ primary peritoneal cancer; **Dabrafenib and Trametinib** for treating skin cancer (Stage III melanoma); **Gemtuzumab Ozogamicin** for treating Leukaemia; **Nivolumab** for treating head and neck cancer, and **Nivolumab and Ipilimumab** for treating renal cell carcinoma, are repositioned from CCF Medical Assistance Programme (First Phase Programme) to SF with effect from 14 December 2024. New applications and renewal applications approved on or after the effective date will be subsidised by SF. For applications already approved before the effective date, CCF subsidy will be provided until end of treatment of the applications.

# The concerned drugs are under Capping Programmes where free drugs are subsequently provided through designated community pharmacies. For details, please refer to the [\[Information Sheet\]](#).

**Self-financed Drugs supported by the Samaritan Fund (SF) and Community Care Fund (CCF) Medical Assistance Programme (First Phase Programme) (for specified self-financed cancer drugs)**

Specialties	Clinical Indications	Drugs	SF	CCF Medical Assistance Programme (1st Phase Programme)
Haematology	Acute lymphoblastic leukaemia	Dasatinib, Inotuzumab Ozogamicin, Ponatinib	✓	
	Acute myeloid leukaemia	Azacitidine and Venetoclax <sup>#</sup> , Gemtuzumab Ozogamicin <sup>~</sup> , Gilteritinib <sup>#</sup> , Midostaurin <sup>#</sup>	✓	
	Aggressive systemic mastocytosis / systemic mastocytosis with associated haematological neoplasm / mast cell leukaemia	Midostaurin <sup>^#</sup>	✓	
	Chronic immune thrombocytopenia	Eltrombopag	✓	
	Chronic lymphocytic leukaemia	Acalabrutinib <sup>**</sup> , Ibrutinib <sup>**</sup> , Obinutuzumab, Rituximab <sup>*</sup>	✓	
		Ibrutinib <sup>^**</sup>		✓
	Chronic myeloid leukaemia	Dasatinib, Nilotinib, Ponatinib	✓	
	Classical Hodgkin Lymphoma (cHL)	Pembrolizumab <sup>*</sup>		✓

Specialties	Clinical Indications	Drugs	SF	CCF Medical Assistance Programme (1st Phase Programme)
	Diffuse large B-cell lymphoma (DLBCL)	Polatuzumab Vedotin and Rituximab*, Polatuzumab Vedotin, Rituximab* and Bendamustine*		✓
	Follicular lymphoma	Bendamustine* and Obinutuzumab, Obinutuzumab, Rituximab*	✓	
	Graft versus host disease	Ruxolitinib <sup>#</sup>	✓	
	Mantle cell lymphoma	Ibrutinib <sup>**</sup>	✓	
		Acalabrutinib <sup>**</sup>		✓
	Multicentric Castleman's disease (MCD)	Siltuximab	✓	
	Multiple myeloma	Bortezomib*, Carfilzomib, Lenalidomide <sup>**</sup> , Pomalidomide <sup>**</sup> , Lenalidomide <sup>**</sup> and Bortezomib*	✓	
		Daratumumab* and Bortezomib*, Daratumumab* and Lenalidomide <sup>**</sup> , Isatuximab and Pomalidomide <sup>**</sup> , Ixazomib <sup>#</sup> and Lenalidomide <sup>**</sup>		✓
	Multiple myeloma / Non-Hodgkin's lymphoma	Plerixafor	✓	
	Myelofibrosis-related splenomegaly or symptoms	Ruxolitinib <sup>#</sup>	✓	

Specialties	Clinical Indications	Drugs	SF	CCF Medical Assistance Programme (1st Phase Programme)
	Paroxysmal nocturnal haemoglobinuria	Eculizumab	✓	
	Prophylaxis of cytomegalovirus reactivation and disease in recipients of an allogeneic haematopoietic stem cell transplant	Letermovir	✓	
	Severe aplastic anaemia	Eltrombopag <sup>#</sup>	✓	
	Systemic AL amyloidosis	Daratumumab* and Bortezomib*	✓	
	Systemic anaplastic large cell lymphoma (sALCL)	Brentuximab Vedotin	✓	
	CD30+ Hodgkin lymphoma/ CD30+ cutaneous T-cell lymphoma	Brentuximab Vedotin	✓	
	Transfusion-dependent anaemia <sup>^</sup>	Luspatercept <sup>^</sup>	✓	
	Waldenström's macroglobulinaemia (WM)	Ibrutinib <sup>**</sup>		✓
		Zanubrutinib <sup>**</sup>	✓	✓
Respiratory Medicine	Idiopathic pulmonary fibrosis	Nintedanib (Ofev)	✓	
	Severe persistent confirmed allergic IgE mediated asthma	Omalizumab	✓	
	Severe refractory eosinophilic asthma	Mepolizumab, Benralizumab	✓	
	Severe asthma with Type 2 inflammation	Dupilumab	✓	

Specialties	Clinical Indications	Drugs	SF	CCF Medical Assistance Programme (1st Phase Programme)
Rheumatology	Ankylosing spondylitis	Adalimumab, Certolizumab Pegol, Etanercept, Golimumab, Infliximab, Secukinumab, Updacitinib	✓	
	Eosinophilic granulomatosis with polyangiitis (EGPA)^	Mepolizumab^	✓	
	Rheumatic disease associated progressive fibrosing interstitial lung disease (PF-ILD)	Nintedanib(Ofev)	✓	
	Psoriatic arthritis	Adalimumab, Certolizumab Pegol, Etanercept, Golimumab, Guselkumab, Infliximab, Risankizumab, Secukinumab, Tofacitinib, Updacitinib, Ustekinumab	✓	
	Rheumatoid arthritis	Abatacept, Adalimumab, Baricitinib, Certolizumab Pegol, Etanercept, Golimumab, Infliximab, Sarilumab, Tocilizumab, Tofacitinib, Upadacitinib	✓	
	Refractory rheumatoid arthritis	Rituximab*	✓	



Specialties	Clinical Indications	Drugs	SF	CCF Medical Assistance Programme (1st Phase Programme)
	Refractory giant cell arteritis	Tocilizumab	✓	
	Severe, active non-life-threatening granulomatosis with polyangiitis / microscopic polyangiitis	Rituximab*	✓	
	Systemic lupus erythematosus (SLE)	Anifrolumab, Belimumab	✓	
Nephrology	Autosomal dominant polycystic kidney disease	Tolvaptan (Jinarc)	✓	
Neurology	Relapsing remitting multiple sclerosis	Cladribine	✓	
	Secondary progressive multiple sclerosis (SPMS)	Siponimod	✓	
Oncology	Bladder cancer	Avelumab		✓
		Pembrolizumab*	✓	
	Breast cancer	Abemaciclib <sup>#</sup> , Abemaciclib <sup>#</sup> and Fulvestrant, Everolimus <sup>#</sup> , Palbociclib <sup>#</sup> , Pertuzumab and Trastuzumab*, Ribociclib <sup>#</sup> , Ribociclib <sup>#</sup> and Fulvestrant, Trastuzumab*, Trastuzumab Deruxtecan <sup>^</sup> , Trastuzumab Emtansine	✓	
		Lapatinib, Neratinib		✓

Specialties	Clinical Indications	Drugs	SF	CCF Medical Assistance Programme (1st Phase Programme)
	Colorectal cancer	Cetuximab, Panitumumab	✓	
		Bevacizumab*		✓
	Esophageal squamous cell carcinoma^	Nivolumab^*	✓	
	Gastric carcinoma	Trastuzumab*		✓
	Gastric, gastroesophageal junction or esophageal adenocarcinoma	Nivolumab*		✓
	Gastrointestinal tumour	Sunitinib*	✓	
	Head and neck cancer	Nivolumab*~	✓	
		Pembrolizumab*		✓
	Recurrent high grade glioma	Temozolomide	✓	
	Liver cancer	Lenvatinib**	✓	
		Atezolizumab* and Bevacizumab*		✓
	Lung cancer	Afatinib, Alectinib#, Atezolizumab*, Brigatinib#, Ceritinib#, Crizotinib#, Durvalumab, Lorlatinib^*#, Nivolumab*, Osimertinib**#, Pembrolizumab*	✓	

Specialties	Clinical Indications	Drugs	SF	CCF Medical Assistance Programme (1st Phase Programme)
		Atezolizumab <sup>^</sup> , Lorlatinib*, Nivolumab* and Ipilimumab*, Osimertinib <sup>##</sup> , Pembrolizumab <sup>^</sup> *		✓
	Malignant lymphoma	Rituximab*	✓	
	Malignant pleural mesothelioma <sup>^</sup>	Nivolumab <sup>^</sup> and Ipilimumab <sup>^</sup> *	✓	
	Ovarian cancer	Pegylated Liposomal Doxorubicin		✓
	Epithelial ovarian / fallopian tube / primary peritoneal cancer	Bevacizumab <sup>~</sup> , Olaparib <sup>#</sup>	✓	
		Niraparib <sup>#</sup>		✓
	Pancreatic cancer	Paclitaxel (Albumin)	✓	
	Prostate cancer	Abiraterone <sup>#</sup> , Apalutamide <sup>#</sup> , Enzalutamide <sup>#</sup>	✓	
	Renal cell carcinoma	Axitinib <sup>#</sup> , Nivolumab <sup>~</sup> and Ipilimumab <sup>~</sup> Pazopanib	✓	
		Sunitinib*		✓
	Skin cancer	Dabrafenib <sup>~</sup> # and Trametinib <sup>~</sup> #, Nivolumab*	✓	
	Thyroid cancer	Lenvatinib <sup>##</sup>		✓
	Uterine cancer	Lenvatinib <sup>##</sup> and Pembrolizumab*		✓
Ophthalmology	Macular oedema secondary to / following Central Retinal Vein Occlusion	Aflibercept, Dexamethasone <sup>^</sup> , Ranibizumab	✓	

Specialties	Clinical Indications	Drugs	SF	CCF Medical Assistance Programme (1st Phase Programme)
	Neovascular (wet) age-related macular degeneration	Aflibercept, Faricimab, Ranibizumab	✓	
	Non-infectious intermediate, posterior and panuveitis	Adalimumab	✓	
	Paediatric chronic non-infectious anterior uveitis	Adalimumab	✓	
	Visual impairment caused by diabetic macular oedema	Aflibercept, Dexamethasone^ Faricimab, Ranibizumab	✓	
Endocrinology	Dwarfism	Growth Hormone	✓	
Dermatology	Atopic dermatitis	Abrocitinib, Dupilumab, Upadacitinib	✓	
	Hidradenitis suppurativa	Adalimumab	✓	
	Pemphigus vulgaris	Rituximab*	✓	
	Severe psoriasis	Adalimumab, Etanercept, Guselkumab, Infliximab, Ixekizumab, Risankizumab, Secukinumab, Ustekinumab	✓	
Clinical Immunology	Chronic spontaneous urticaria	Omalizumab	✓	
Paediatrics	Atopic dermatitis	Dupilumab, Upadacitinib	✓	

Specialties	Clinical Indications	Drugs	SF	CCF Medical Assistance Programme (1st Phase Programme)
	CD20 positive diffuse large B-cell lymphoma, Burkitt lymphoma / Burkitt leukaemia or Burkitt-like lymphoma	Rituximab*	✓	
	Classical Hodgkin Lymphoma (cHL)	Pembrolizumab*		✓
	Chronic granulomatous disease	Interferon	✓	
	Cryopyrin-associated periodic syndromes	Canakinumab	✓	
	Familial Mediterranean fever	Canakinumab	✓	
	Hyperimmunoglobulin D syndrome / mevalonate kinase deficiency	Canakinumab	✓	
	Neurofibromatosis	Selumetinib		✓
	Tumour necrosis factor receptor associated periodic syndrome	Canakinumab	✓	
	Severe, active granulomatosis with polyangiitis (GPA) / microscopic polyangiitis (MPA)	Rituximab*	✓	
	Juvenile Idiopathic Arthritis	Abatacept, Adalimumab, Etanercept, Tocilizumab	✓	
	Hidradenitis suppurativa	Adalimumab	✓	

Specialties	Clinical Indications	Drugs	SF	CCF Medical Assistance Programme (1st Phase Programme)
	Severe psoriasis	Adalimumab, Secukinumab	✓	
	Systemic lupus erythematosus (SLE)	Belimumab	✓	
	Systemic juvenile idiopathic arthritis	Canakinumab, Tocilizumab	✓	

Remarks:

- ^ With effect from 14 December 2024.
- \* The designated clinical indications of the same drug supported by different funds are different. Please consult your case doctor for details.
- ~ **Bevacizumab** for treating epithelial ovarian / fallopian tube / primary peritoneal cancer; **Dabrafenib and Trametinib** for treating skin cancer (Stage III melanoma); **Gemtuzumab Ozogamicin** for treating leukaemia; **Nivolumab** for treating head and neck cancer; and **Nivolumab and Ipilimumab** for treating renal cell carcinoma, are repositioned from CCF Medical Assistance Programme (First Phase Programme) to SF with effect from 14 December 2024. New applications and renewal applications approved on or after the effective date will be subsidised by SF. For applications already approved before the effective date, CCF subsidy will be provided until end of treatment of the applications.
- # The concerned drugs are under Capping Programmes where free drugs are subsequently provided through designated community pharmacies. For details, please refer to the [\[Information Sheet\]](#).